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cognitive consequences of cOViD-19: results 
of a cohort study from South America 
Consecuencias cognitivas del COVID-19: Resultados de un estudio de cohorte 
sudamericano
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Carlos MARTÍNEZ1, Micaela ARRUABARRENA1, Ricardo ALLEGRI1,2
ABStrAct
Background: Neurological and psychiatric manifestations associated with SARS-CoV-2 infection have been reported throughout the scientific 
literature. However, studies on post-COVID cognitive impairment in people with no previous cognitive complaint are scarce. Objective: We aim 
to investigate the impact of COVID-19 on cognitive functions in adults without cognitive complaints before infection and to study cognitive 
dysfunction according to disease severity and cognitive risk factors. Methods: Forty-five post-COVID-19 patients and forty-five controls 
underwent extensive neuropsychological evaluation, which assessed cognitive domains such as memory, language, attention, executive 
functions, and visuospatial skills, including psychiatric symptomatology scales. Data were collected on the severity of infection, premorbid 
medical conditions, and functionality for activities of daily living before and after COVID-19. Results: Significant differences between groups 
were found in cognitive composites of memory (p=0.016, Cohen’s d= 0.73), attention (p<0.001, Cohen’s d=1.2), executive functions (p<0.001, 
Cohen’s d=1.4), and language (p=0.002, Cohen’s d=0.87). The change from premorbid to post-infection functioning was significantly different 
between severity groups (WHODAS, p=0.037). Self-reported anxiety was associated with the presence of cognitive dysfunction in COVID-19 
subjects (p=0.043). Conclusion: Our results suggest that the presence of cognitive symptoms in post-COVID-19 patients may persist for 
months after disease remission and argue for the inclusion of cognitive assessment as a protocolized stage of the post-COVID examination. 
Screening measures may not be sufficient to detect cognitive dysfunction in post-COVID-19 patients.
Keywords: COVID-19; Neuropsychology; Cognitive Dysfunction; Executive Function; Memory.
reSUMeN
Antecedentes: Las manifestaciones neurológicas de la infección por SARS-CoV-2 han sido reportadas en la literatura científica. Sin embargo, 
los estudios cognitivos post COVID-19 en personas sin queja cognitiva previa son escasos. Objetivo: Nuestro objetivo es investigar el impacto 
cognitivo del COVID-19 en adultos sin quejas cognitivas previas a la infección y estudiar el desempeño cognitivo de acuerdo a la severidad de 
la enfermedad y a los factores de riesgo cognitivo. Métodos: Cuarenta y cinco pacientes post COVID-19 y cuarenta y cinco controles sanos 
apareados por edad, género y educación realizaron una evaluación neuropsicológica, que evalúa memoria, lenguaje, atención, funciones 
ejecutivas, habilidades visuoespaciales, incluyendo además escalas de sintomatología psiquiátrica, y la recopilación de datos sobre la 
severidad de la infección, la salud premórbida y la funcionalidad. Resultados: Se encontraron diferencias significativas entre los grupos en 
los compuestos cognitivos de memoria (p=0,016, d de Cohen= 0,73), atención (p<0,001, d de Cohen= 1,2), funciones ejecutivas (p<0,001, d 
de Cohen=1,4) y lenguaje (p=0,002, d de Cohen=0,87). El cambio del funcionamiento premórbido al funcionamiento posterior a la infección, 
fue significativamente diferente entre los grupos de gravedad (WHODAS; p=0,037). La ansiedad autoinformada se asoció con la presencia 
de disfunción cognitiva en los sujetos de COVID-19 (p=0,043). Conclusión: Nuestros resultados sugieren que los síntomas cognitivos en 
pacientes post COVID-19 pueden permanecer hasta tres meses después de la remisión de la enfermedad. Este estudio aboga a favor de 
incluir la evaluación cognitiva como una etapa protocolizada del examen post COVID-19. Es posible que las medidas de cribado no sean 
suficientes para detectar la disfunción cognitiva en los pacientes post COVID-19.
Palabras clave: COVID-19; Neuropsicología; Disfunción Cognitiva; Función Ejecutiva; Memoria.
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iNtrODUctiON
Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has infected over 110 million people worldwide, result-
ing in more than 2 million deaths globally. The predominant 
consequences of the virus are respiratory; however, neurologi-
cal manifestations of COVID-19¹ have been reported with a 
frequency of 36.4 to 84%². Neurological manifestations include 
altered consciousness, acute neuropathies, cognitive impair-
ment, and skeletal muscle injury. It is important to note that 
neurological symptoms were also found in patients who did 
not present with the typical signs of COVID-19 as the only 
manifestation³. 
Neurological manifestations associated with SARS-CoV-2 
infection usually occur during the second week of illness and 
are mainly observed in critically ill patients⁴. While psychiatric 
and neurological alterations have been consistently reported5,6,7, 
few studies currently report cognitive deficits among COVID-19 
survivors8,9,10,11,12. These studies report cognitive deficits in mild 
and moderate cases of the infection13, with significant impair-
ment of executive functions, memory, and attention14. In addi-
tion, cognitive deficits have been reported in studies performed 
in the acute phase of the infection15 and in recovered patients.
With more than 40 million confirmed cases and 1.5 million 
deaths, Latin America has been one of the regions most affected 
by the pandemic16. However, evidence of post-COVID cognitive 
impairment in the region is scarce. Neurological alterations in 
post-COVID-19 patients were reported in a cohort study of 63 
hospitalized post-COVID patients17. The most frequent neu-
rological complications were ischemic stroke in 30 patients 
(47.6%) and encephalopathy in 17 patients (27%), followed 
by seizures, hemorrhagic stroke, and headache. These studies 
highlight the need to evaluate cognitive symptoms after the 
disease to assess patients’ cognitive status and design reha-
bilitation strategies.
Regarding the study of post-COVID cognitive impairment 
in the Latin American region, Del Brutto13 compared cognitive 
change (decline) in a cohort of middle-aged and older adults 
from a community in Atahualpa. The study compared changes 
between pre-pandemic measures and post-pandemic assess-
ment and between seropositive and seronegative individuals. 
Results show a 21% cognitive decline in the sample of COVID-
19 survivors versus only 2% of the seronegative group. This 
study, as well as others18,19,20, assessed cognitive dysfunction 
using cognitive screening tools such as the Montreal Cognitive 
Assessment (MoCA), Mini-Mental State Examination (MMSE), 
and Telephone Interview for Cognitive Status (TICS). 
The aim of this study was to describe the cognitive profile 
of a cohort of COVID-19 survivors that attended a neurologi-
cal clinic in Buenos Aires, Argentina. In addition, the impact of 
COVID-19 on cognitive functions in adults without cognitive 
complaints before infection, cognitive dysfunction according 
to disease severity, and cognitive risk factors were evaluated. 
MetHODS
Study design and participants
We report data from 45 post-COVID-19 patients recruited 
from an outpatient neurological clinic by attending neurologists. 
Patients were evaluated for an average of 142 days after illness. 
Inclusion criteria were: a positive SARS-CoV2 RT-PCR result 
from nasopharyngeal swabs, age > 18 years, and no pre-infection 
cognitive complaint. Exclusion criteria were: significant upper 
limb impairment, visual acuity or visual field deficits, drug use, 
or psychiatric disorders. The local ethics committee approved 
the protocol and all subjects signed an informed consent form 
before assessments. 
Neuropsychological assessment was performed using an 
extensive cognitive battery. Additionally, data were collected 
on the characteristics of the acute COVID-19 episode, pre-
morbid medical conditions, and functionality for activities of 
daily living (ADL) pre-and-post COVID-19. Disease severity 
was classified as asymptomatic, mild, moderate, and severe 
according to WHO21. The study was designed in three steps to 
answer three specific questions: 1) Are there cognitive deficits 
in post-COVID-19 subjects with a cognitive complaint? 2) Is 
it possible to describe a cognitive profile for these patients? 
3) Are there identifiable risk factors for the occurrence cogni-
tive complaints? First, subjects were compared with forty-five 
healthy control (H.C.) subjects with no history of SARS-CoV-2 
infection matched for sex, age, and educational level. In a sec-
ond instance of the study, we created cognitive composites to 
better understand cognition in the domains. The development 
of a comprehensive cognitive battery for post-COVID patients 
took several months. For this reason, some patients did not 
receive the complete assessment regardless of their cognitive 
performance. To avoid sample bias, only subjects with com-
plete data (N=29) and their matched controls were included. 
Finally, in the third instance, a risk model was constructed by 
logistic regression for the clinical and demographic variables 
evaluated in the study.
Outcomes
Participants underwent a comprehensive neuropsychologi-
cal evaluation that included anxiety, depression, and function-
ality scales. In addition, assessment of clinical illness charac-
teristics and risk factors were self-reported using structured 
questionnaires and scales. 
cognitive assessment
Cognitive screening was performed using the Argentine ver-
sion of the MoCA22. The extensive neuropsychological assess-
ment included attention, memory, language, executive functions, 
and visuospatial skills tests. Attention was assessed with Trail 
Making A23, Digit Span Forwards24, and Digit-Symbol Coding25. 
Memory was tested using Craft Story 2126, Rey Auditory Verbal 
Learning Test27, and Delayed Recall from the Benson Figure 
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Test28. Executive function assessment included Trail Making B23, 
Wisconsin Card Sorting Test29, Stroop Test30, and phonological 
fluency31. Benson Figure and Clock Drawing Test32 assessed 
visuospatial skills. Finally, the language was assessed using the 
Multilingual Naming Test33 and semantic fluency34.
Neuropsychiatric and functional assessment
The Hospital Anxiety and Depression Scale35 was admin-
istered for neuropsychiatric screening purposes. In addition, 
WHODAS 2.0 Functional Scale21 was used to assess pre- and 
post-COVID-19 changes in ADL. Subjects were instructed to 
answer the questions regarding their pre-infectious status. 
Disease severity and risk factors for cognitive 
impairment assessment
Participants completed the CAIDE (Cardiovascular Risk 
Factors, Aging, and Incidence of Dementia) Dementia Risk 
Score, a test for estimating risk of dementia in the general 
population36. This test combines self-reported measures of 
age, education, sex, hypertension, body mass index, hypercho-
lesterinemia, and physical activity into a dementia risk score. 
In addition, we assessed risk factors for COVID disease sever-
ity such as diabetes, smoking, cardiac disease, and chronic 
obstructive pulmonary disease (COPD) using an ad hoc yes/
no binary questionnaire. 
Statistical analysis
All variables were tested graphically and analytically for 
normality assumptions. For variables with normal distribu-
tion, summary statistics are presented as mean and standard 
deviation (S.D.), and for variables without normal distribution, 
median (M) and interquartile range (IQR) are used. Group dif-
ferences were evaluated using independent t-tests, one-way 
ANOVA, and the Mann-Whitney U or Kruskal-Wallis test was 
used according to data distribution. To prevent an increase in 
the family-wise error rate (FWER) associated with multiple inde-
pendent hypothesis testing, we used the Benjamini Hochberg 
procedure when more than four independent variables were 
analyzed in one group. We also approached the FWER problem 
with the creation of composites (see next section). 
A risk model for cognitive impairment diagnosis was built. 
In this cohort, cognitive impairment diagnosis was defined as 
a Z score of -1.5 or less in at least one cognitive composite. A 
logistic regression model was used to assess this risk. Results 
are presented as odds ratios (OR) for every risk factor and accu-
racy model through Akaike information criteria (AIC). For all 
tests, a significance level was set at p<0.05.
Results from neuropsychological tests were calculated 
using composite scores. The composite quantifies cognitive 
function across multiple tests with greater statistical power 
than individual measures. It consolidates type 1 error into a 
single outcome. Domain-specific composites were constructed 
using the tests from the neuropsychological battery that bet-
ter predicted cognitive impairment for each cognitive domain. 
The domain-specific composite outcome was calculated 
as follows: 
• Scores for each contributing test were converted to Z 
scores according to normative data. When necessary, Z 
scores were corrected so that positive scores reflected 
better performance and negative scores reflected worse 
performance;
• Memory Composite: RAVLT learning score and RAVLT 
Delayed Score, Benson Figure Test Delayed score;
• Attention Composite: TMT A, Digit span Forwards;
• Executive Composite: TMT B, Digit span Backward, 
Phonological fluency;
• Language Composite: MINT score, Semantic fluency.
reSUltS
Demographic results
The characteristics of the complete cohort of 45 post-
COVID-19 patients (M = 50) and 45 H.C. matched by age, sex, 
and education are shown in Table 1. There were no differences 
between patients and H.C. in the estimated risk for dementia 
as measured by the CAIDE Score (p=0.3).
Data are reported as median (interquartile range), n (%), 
or median (standard deviation); 2Wilcoxon rank sum test or 
Pearson’s Chi-squared test; CAIDE: Cardiovascular Risk Factors, 
Aging, and Incidence of Dementia Dementia Risk Score.
Table 1. Demographic results.
Characteristic Healthy controls (N = 45) Post-COVID (N = 45) p-value2
Age (y) 57 (46, 64) 50 (43, 63) 0.4
Sex: female 20 (44%) 22 (49%) 0.7
Education (y) 17.00 (15.00, 18.00) 17.00 (15.00, 18.00) >0.9
Duration of infection (days) - 15.5 (2.2)
Evaluation post-infection (days) - 142 (75.9)
Hospitalization - 14 (31%)
CAIDE dementia score 6.00 (3.00, 7.00) 5.00 (2.00, 7.00) 0.3
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General cognitive performance and 
neuropsychiatric symptomatology
When comparing H.C. and patients on individual test mea-
sures (Table 2), no significant differences were found in the 
complete sample for the screening measures (MoCA p=0.15; 
MMSE p=0.4). However, significant differences were found 
between groups in all of the memory and attention scales. 
Language measures were significantly lower for semantic and 
phonological fluency in the patient group, but not for nam-
ing. Significant differences in executive performance were 
found between groups, with a better performance of H.C. in 
alternating attention, categorization, and perseverations. No 
differences were found in the visuospatial domain in copying 
complex figures; however, significantly lower performance was 
observed in the patient group for the CDT. It is important to 
note that this test does not exclusively assesses visuospatial 
abilities but also includes semantic and executive components. 
The neuropsychiatric variables of depression and anxiety did 
not differ between groups.
cognitive results by domain, severity, and impact on 
functionality
The complete cognitive battery including memory, atten-
tion, language and executive composite scores, neuropsychi-
atric, functional, and risk factor assessment was administered 
to a subsample of 29 patients and 29 controls. 
Results from composite scores show deficits in memory 
(p=0.016, d= 0.73), attention (p<0.001, d=1.2), executive func-
tions (p<0.001, d=1.4), and language (p=0.002, d=0.87). Cohen’s 
D was calculated for each composite to measure effect size. 
Effects for executive functions, attention, and language were 
large and effects for memory were intermediate (Table 3).
Table 2. General cognitive results. 
Healthy controls  
(N = 451)
Post-COVID  
(N = 451) p-value
2
Screening
MoCA total 27.22 (1.99) 26.49 (2.90) 0.4
MMSE/MoCA crosswalk 27.22 (1.99) 26.04 (3.33) 0.15
CDT 9.78 (0.59) 9.13 (1.35) 0.007
Memory
RAVLT Total 50 (9) 43 (13) 0.018
RAVLT delayed recall 10.2 (2.9) 8.2 (3.5) 0.007
Benson figure delayed recall 12.27 (2.65) 10.50 (3.25) 0.009
Language
MINT/BNT crosswalk 30.31 (1.55) 29.47 (2.12) 0.058
Semantic fluency 22.6 (4.5) 18.9 (5.2) <0.001
Phonological fluency (p) 17.9 (4.3) 14.1 (4.6) <0.001
Attention
Digit span (direct) 6. 89 (0.93) 5.89 (1.30) <0.001
Digit span (indirect) 5.09 (0.95) 4.04 (1.19) <0.001
Trail making test A 29 (7) 47 (25) <0.001
WAIS-IV Coding 13.5 (2.9) 11.8 (3.7) 0.010
Executive system
Trail making test B 62 (22) 107 (76) <0.001
WCST cat 6.00 (0.00) 5.59 (1.04) 0.014
WCST pers 0.89 (1.29) 2.94 (4.63) 0.010
Visuospatial Benson figure copy 16.24 (0.98) 16.26 (3.10) 0.2
Neuropsychiatric
HADS anxiety 8.8 (3.4) 8.5 (3.4) 0.8
HADS depression 6.1 (3.7) 5.9 (3.5) 0.7
1Data are reported as mean (standard deviation); 2 Wilcoxon rank-sum test; MoCA: Montreal Cognitive Assessment; CDT: Clock Drawing Test; RAVLT: Rey Auditory 
Verbal Learning Test; MINT/BNT crosswalk: Multilingual Naming Test / Boston Naming Test crosswalk; WAIS IV: Wechsler Adult Intelligence Scale IV; WCST: 
Wisconsin Card Sorting Test; HADS: Hospital Anxiety and Depression Scale.
Table 3. Results of cognitive composites. 
Healthy control (N = 291) Post-COVID (N = 291) p-value2 Effect size3
Memory (composite) 0.20 (-0.19, 0.60) -0.19 (-0.76, 0.06) 0.016 0.734
Attention (composite) -0.12 (-0.57, 0.28) -1.16 (-1.66, -0.60) <0.001 1.272
Executive (composite) 0.10 (-0.02, 0.31) -0.62 (-1.52, -0.21) <0.001 1.483
Language (composite) 0.05 (-0.22, 0.42) -0.49 (-0.76, 0.04) 0.002 0.877
1Data are reported as median (interquartile range); 2Wilcoxon rank sum test; 3Cohen’s D.
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The patient group was divided according to illness severity 
using the WHO severity scale (Table 4 and Figure 1). Results 
show no significant differences between the different cognitive 
composites across the different severity groups.
The change in functionality was assessed with the WHODAS 
2.0, which inquires on different aspects of functioning before 
and after SARS-CoV-2 infection. The total score was signifi-
cantly different between severity groups (p=0.011), indicating 
a change in functionality post-SARS-CoV-2 infection according 
to disease severity. In addition, WHODAS subscore results show 
a differential impact of cognitive functionality, social partici-
pation, and mobility between disease severity levels (p=0.007).
Predictors of cognitive impairment
A logistical regression model was built to identify predic-
tors of cognitive impairment among post-COVID-19 subjects. 
The model with the best predictive performance (AIC: 38.3) did 
not identify common clinical risk factors as predictors of post-
COVID-19 cognitive impairment. In addition, only self-reported 
anxiety measured by the Hospital Anxiety and Depression Scale 
(HADS) showed significant results (Table 5). 
DiScUSSiON
The SARS-CoV2 infection produces multiple organ failure 
leading to a wide variety of symptomatology and respiratory 
syndromes. Neurological manifestations are frequent2 and 
diverse, and may include cognitive impairment12. This study 
focused on the description of cognitive performance in previ-
ously healthy adults with no history of cognitive impairment. 
Our results advocate for the importance of including cognitive 
assessment as a protocolized stage of post-COVID examination. 
Table 4. Cognitive domain performance across different COVID-19 severity levels. 
Ambulatory: mild disease  
(N = 191)
Hospitalized: moderate and 
severe disease (N = 91) p-value
2
Memory (composite) -0.19 (-0.69, -0.01) -0.35 (-0.98, 0.06) 0.8
Attention (composite) -1.16 (-1.60, -0.63) -1.31 (-1.90, -0.72) 0.6
Executive (composite) -0.62 (-1.50, -0.32) -0.74 (-1.87, -0.21) 0.8
Language (composite) -0.54 (-0.71, 0.11) -0.40 (-0.76, -0.26) >0.9
1Data are reported as median (interquartile range); 2Kruskal-Wallis rank sum test.
Figure 1. Cognitive domains across illness severity levels in in healthy controls.
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We studied patients that attended a Neurological Clinic with 
a post-COVID cognitive complaint. Our results show that defi-
cits can be identified predominantly in executive functions and 
attention, and have a smaller effect on memory and language. 
Furthermore, these deficits do not vary according to disease 
severity as measured by the WHO’s COVID-19 severity scale37. 
Notwithstanding, self-reported cognitive functionality, social 
participation, and mobility differ according to disease severity, 
indicating that the impact of cognitive impairment is higher 
when illness severity is increased. 
Regarding the affected cognitive domains, our results are 
consistent with other studies that found a similar cognitive pro-
file, with impaired attention and executive functions in patients 
one to six months after infection, with severity ranging from 
asymptomatic18 to moderate and severe10,15,38. Furthermore, 
these deficits are reported in the acute phase of the disease39,40 
to up to 6 months after recovery13. 
Our study reported that cognitive dysfunction did not vary 
significantly between the mild and moderate severity groups. 
However, this result must be interpreted with caution because 
our sample size was small and, most importantly, unevenly 
distributed across severity levels. Most of the patients were 
classified as mild (n=19), and very few patients as moderate 
COVID-19 (N=9). Conflicting results have been found in other 
studies that looked into the correlation between cognition and 
cognitive performance. A group of studies found no association 
between the severity of COVID-19 and cognitive functioning12,20. 
In contrast, others found that global cognitive impairment and 
executive dysfunction correlated with the severity of respira-
tory symptoms and poorer pulmonary function15. Our study 
complements previous research but is not conclusive enough 
to draw conclusions. Prospective studies specifically designed 
to study cognitive performance and cognitive profile across 
different disease severity groups are needed. 
Regarding possible predictors of cognitive impairment, 
we found no influence of commonly studied risk factors for 
dementia (diabetes, smoking, age, and education) nor the well-
known risk factors for severe COVID-19 respiratory illness. Our 
study, however, found that anxiety was a predictive factor of 
cognitive impairment. It is a well-known that mood disorders, 
including anxiety, can cause cognitive dysfunction41. However, 
our study did not find significant differences between groups 
in anxiety or depression, and levels of anxiety of our cohort fell 
into the normal range in both groups. Therefore, the results 
must be regarded with caution.
A possible understanding of COVID-19 cognitive impair-
ment may be based on records of other coronaviruses (such 
as SARS and MERS), in which long-term neuropsychological 
deficits were registered42. In these outbreaks, cognitive defi-
cits were also centered on attention, executive functions, and 
memory. Furthermore, cognitive dysfunction in patients with a 
viral infection such as Human Immunodeficiency Virus (HIV) 
has also been reported in prior studies, in which deficits in 
attention, learning, and memory functions were reported43. 
Additionally, the Zika virus has also been reported to leave 
long-term cognitive sequelae44. The COVID-19 pandemic has 
brought to our attention the need to better understand the 
role of viral infections in cognitive impairment.
Finally, our results suggest that cognitive symptoms may 
be expected in patients after COVID-19 recovery and may last 
months after illness remission. Thus, our results underscore 
the need to include a cognitive assessment in post COVID-19 
follow-ups to guide possible cognitive rehabilitation treatment.
Limitations of our study include heterogeneity at the time 
of evaluation, small sample size, and unequal frequency of 
disease severity levels, as well as the non-inclusion of patients 
with severe disease. Future studies should include a systematic 
analysis with larger patient cohorts and long-term follow-up. 
Another limitation of our study is the absence of a cognitive 
assessment before infection, which would allow a more accurate 
estimation of the impact of COVID-19 on cognitive functions. 
In addition, the subjects included in the study had requested a 
Table 5. Predictors of cognitive impairment.
Characteristic OR1 95% CI1 p-value
CAIDE dementia score 0.21 0.00, 1.15 0.14
Age (y) 1.19 0.89, 1.75 0.3
Sex
Male 49.7 0.66, 41986.3 0.15
Female 49.8 0.67, 6.54 0.14
Education (y) 1.00 0.26, 6.54 >0.9
Obesity 4472.3 0.97, 5012838000 0.11
Hypertension 0.00 NA, 14383040000 >0.9
HADS Depression 2.22 1.17, 6.54 0.056
HADS Anxiety 0.49 0.18, 0.84 0.043
Physical activity 0.21 0.00, 10.1 0.4
1Data are reported as odds ratio (OR) and 95% confidence interval (95%CI); CAIDE: Cardiovascular Risk Factors, Aging, and Incidence of Dementia - Dementia 
Risk Score; HADS: Hospital Anxiety and Depression Scale. NA: Not available.
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medical consultation, which could result in a population with 
elevated anxiety symptoms that could affect cognitive perfor-
mance. Finally, a considerable number of subjects did not fully 
complete the cognitive assessment battery, so composites were 
generated to avoid sample bias between groups.
Results indicated that commonly used screening meth-
ods in the elderly population (MMSE, MoCA) are not sensi-
tive enough to detect cognitive impairment in post-COVID 
patients. A more exhaustive neuropsychological examination 
is needed. Our study is among the first in our region to use a 
broad and robust neuropsychological battery, which is sensi-
tive for detecting cognitive dysfunction post-COVID-19. The 
neuropsychological tests included in our composites could be 
recommended as an adequate neuropsychological battery for 
the Latin American population. 
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